Onasemnogene abeparvovec for spinal muscular atrophy: The costlier drug ever
The US Food and Drug Administration (FDA) on May 24, 2019 approved onasemnogene abeparvovec, a drug for the treatment of spinal muscular atrophy (SMA). The drug, developed by the Swiss drugmaker Novartis, has been marketed under the trade name Zolgensma. The drug has been approved to be used in chil...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Editorial |
| 言語: | 英語 |
| 出版事項: |
2019
|
| オンライン･アクセス: | https://doi.org/10.4103/ijabmr.ijabmr_190_19 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|